This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insider Watch: 3 CEOs Buying the Dip
by Derek Lewis
Large-cap stocks CHD, LLY, and VTRS have seen their respective CEOs make purchases over the last month. What do they see?
Zacks Investment Ideas feature highlights: Eli Lilly, Eaton and Interactive Brokers
by Zacks Equity Research
Eli Lilly, Eaton, and Interactive Brokers post standout Q2 results, with booming sales, raised guidance, and record-breaking growth.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
These 3 Companies are Seeing Supercharged Sales Growth
by Derek Lewis
The 2025 Q2 earnings season is now behind us, with the period largely positive and resilient. Throughout the period, these three companies posted notably strong sales growth.
Viking Therapeutics Loses 20% in a Month: How to Play the Stock
by Sundeep Ganoria
VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
by Kinjel Shah
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
GSK Adds Around $5B in a Month: Here's How to Play the Stock
by Kinjel Shah
GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.
Pfizer's Golden Cross Signals Strength: How to Play the Stock
by Kinjel Shah
Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.
NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?
by Ahan Chakraborty
Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
by Zacks Equity Research
BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.
The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies
by Zacks Equity Research
Zacks spotlights Eli Lilly, Oracle, Procter & Gamble, and microcap Comstock Holding, with pharma and staples facing pressure while Oracle and Comstock show momentum.
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
by Kinjel Shah
AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.
Top Stock Reports for Eli Lilly, Oracle & Procter & Gamble
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly, Oracle, and Procter & Gamble, as well as a micro-cap stock, Comstock.
Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?
by Kinjel Shah
Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.
What Is the Intent Behind AbbVie's Recent Acquisition Spree?
by Zacks Equity Research
ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
by Ahan Chakraborty
NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.
Company News for Aug 27, 2025
by Zacks Equity Research
Companies in The News Are: BNS,SMTC,LLY,SATS,T
Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?
by Kinjel Shah
LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.
LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?
by Kinjel Shah
Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.
Durable Goods Orders Decreased Less Than Expected
by Zacks Equity Research
Durable Goods Orders Decreased Less Than Expected
Immuneering Stock Rises 21.7% on Supply Agreement With LLY
by Zacks Equity Research
IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.
Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?
by Ahan Chakraborty
NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.
Pre-Markets in Red but Improving on New Data
by Mark Vickery
We appear to be bouncing around a bit more in recent trading days after a steadier level following August 2nd lows.
AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.
RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?
by Zacks Equity Research
Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.